Opposing functions of gut immunomodulatory metabolites on CAR-T therapy.

Gut metabolites have opposing effects on CAR-T cell therapy outcomes, with valeric acid improving and indole metabolites impairing treatment efficacy.

• Why it matters: Understanding how gut microbiome-derived metabolites influence CAR-T therapy is crucial, as nearly half of patients relapse or progress, highlighting a significant treatment challenge.
• What they did: Researchers analyzed 129 patients using shotgun metagenomics and mass spectrometry to measure gut metabolites, focusing on short-chain fatty acids and indole compounds before therapy.
• The result: Valeric acid supplementation enhanced CAR-T efficacy, while indole-3-carboxaldehyde and isovaleric acid impaired it, suggesting metabolite-guided strategies could optimize treatment success.